Clomipramine
Anafranil, Clomipramine (clomipramine) is a small molecule pharmaceutical. Clomipramine was first approved as Anafranil on 1989-12-29. It is used to treat depressive disorder, obsessive-compulsive disorder, pain, panic disorder, and psychotic affective disorders in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter. In addition, it is known to target sodium-dependent dopamine transporter, G protein-activated inward rectifier potassium channel 4, and G protein-activated inward rectifier potassium channel 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Anafranil, Clomipramine (discontinued: Clomipramine)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| anafranil | New Drug Application | 2024-11-26 |
| clomipramine hcl | ANDA | 2024-12-09 |
| clomipramine hydrochloride | ANDA | 2025-06-11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 2 | — | 1 | 2 | 5 | 10 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | 2 | 2 | 5 | 10 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 2 | 3 | 5 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | 1 | 3 | 4 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | — | 1 | 1 | 2 |
| Atrophy | D001284 | — | — | — | — | — | 1 | — | 1 |
| Panic disorder | D016584 | EFO_0004262 | F41.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Compulsive personality disorder | D003193 | — | F60.5 | — | 1 | 1 | — | 4 | 6 |
| Premature ejaculation | D061686 | — | F52.4 | 1 | 2 | 1 | — | — | 4 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 2 | 1 | — | — | 3 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Taste disorders | D013651 | — | — | — | — | — | — | 3 | 3 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Clomipramine |
| INN | clomipramine |
| Description | Clomipramine is a dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias. It has a role as a serotonergic antagonist, a serotonergic drug, a serotonin uptake inhibitor, an EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor, an antidepressant and an anticoronaviral agent. It is functionally related to an imipramine. It is a conjugate base of a clomipramine(1+). |
| Classification | Small molecule |
| Drug class | antidepressants (imipramine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21 |
Identifiers
| PDB | — |
| CAS-ID | 303-49-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL415 |
| ChEBI ID | 47780 |
| PubChem CID | 2801 |
| DrugBank | DB01242 |
| UNII ID | NUV44L116D (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Clomipramine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,429 documents
View more details
Safety
Black-box Warning
Black-box warning for: Anafranil, Clomipramine hcl, Clomipramine hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,797 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use